TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Comparison

Brand-Name vs Compounded GLP-1

Same fields, same evidence rules, both sides. No preselected winner.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

This comparison sets out where the two options genuinely differ — mechanism, regulatory status, evidence base, cost path and practical trade-offs — and where the difference is smaller than it is usually presented. It does not recommend one for you.

Answer last reviewed:
Approved product against compounded preparation
Approved product against compounded preparation
AttributeFDA-approved tirzepatide (Zepbound, Mounjaro)Compounded tirzepatide
Regulatory statusApproved finished drug productNot an FDA-approved product
Generic equivalentNo generic tirzepatide existsNot a generic and not therapeutically equivalent
Manufacturing standardManufactured under CGMPDepends on the compounder's registration class
Clinical trial evidenceStudied in the registration trialsTrials studied the approved product, not this preparation
LabellingFDA-approved labellingSupplied by the compounder
PresentationManufacturer's pens or vialsVaries; multi-dose vials add a measuring step
Price read on the seller’s own page——

A dash means no figure held. How we grade evidence.

No provider may describe a compounded preparation as FDA-approved or as generic Zepbound. Both statements are false, and both are common.
503A pharmacy against 503B outsourcing facilityStatutory distinction · pending legal review
503A pharmacy against 503B outsourcing facility
Requirement503A compounding pharmacy503B outsourcing facility
Compounds pursuant toA prescription for an identified individual patientMay compound without patient-specific prescriptions
FDA registrationNot registered as an outsourcing facilityRegisters with FDA
CGMP requirementsNot required to meet CGMPMust comply with CGMP — though registration alone is not evidence of compliance
Primary oversightState board of pharmacyFDA, on a risk-based inspection schedule
Adverse-event reportingNot required under 503ARequired to report adverse events to FDA
Product approval statusNot an FDA-approved productNot an FDA-approved product
What registration establishesNot applicableFDA received the required information, nothing more Verified
Neither route produces an FDA-approved medicine. Registration and inspection are not approval, and no accreditation changes that.
Official verification routescaptured 2026-07-26

Every one of these is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.

Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.
Where the cost difference actually sits
MedicationOption A — not capturedOption B — not capturedRequired feesOption A — not capturedOption B — not capturedTwelve-month totalOption A — not capturedOption B — not capturedOption AOption B
Show this figure as a table
Data table
ItemOption AOption B
Medicationnot capturednot captured
Required feesnot capturednot captured
Twelve-month totalnot capturednot captured
Filled from captured records. An empty bar is a gap in our research, not a zero.

The short version

Brand-name GLP-1 medicines are FDA-approved finished products. They include Wegovy and Ozempic (semaglutide), Zepbound and Mounjaro (tirzepatide) and Lilly's daily pill Foundayo. Compounded semaglutide and compounded tirzepatide are pharmacy preparations made with the drugs in those products. They are not FDA-approved, they are not generics, and they are not the same products. There is no compounded version of Foundayo.

The brand route makes sense when coverage or a program cuts the price. The clearest case is the Medicare GLP-1 Bridge: a $50 copay for Foundayo, Wegovy or the Zepbound KwikPen from July 1, 2026 to December 31, 2027, for eligible enrollees. It also makes sense if you want the product the trials studied. The compounded route is mainly a cash-price decision. It brings less assurance about how the product was made, and the FDA has not finished deciding the regulatory position for either drug.

Where they actually differ

  • Approval and labelled uses. Each brand product has its own approved uses. Compounded semaglutide and tirzepatide have none.
  • Medicare coverage. The GLP-1 Bridge covers three brand products and no compounded ones. Even Zepbound is covered only as the KwikPen, not as vials.
  • The ingredient. FDA has warned that some compounded semaglutide is made from salt forms, such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the one in approved products. See FDA's page on compounded GLP-1s.
  • Pills and drops. Foundayo is an approved oral GLP-1. Compounded "oral", sublingual and dissolving-tablet versions of semaglutide or tirzepatide have no trial evidence that they are absorbed. See GLP-1s without needles.
  • The shortage route. FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage in February 2025. That closed the wider compounding route for both. In April 2026 FDA also proposed not to place semaglutide, tirzepatide or liraglutide on the 503B bulks list.

Where they are more similar than claimed

  • The drug comparison is separate from the brand comparison. In SURMOUNT-5, tirzepatide produced a larger average weight loss than semaglutide (−20.2% vs −13.7% at 72 weeks). That is a difference between two drugs, both tested as manufacturers' products. It says nothing about compounded tirzepatide against brand semaglutide, which no trial has tested.
  • Injections work the same way. Brand and compounded injectables are both given once a week under the skin. The vial-and-syringe step is the practical difference.
  • The same oversight is needed. Both routes need a prescription, a dose plan and follow-up from a licensed clinician.
  • A brand name is not proof. FDA has warned that counterfeit Ozempic has been marketed in the US. A brand pen from an unlicensed seller is not safer than a properly sourced prescription. See counterfeit GLP-1s.
  • Side effects. Stomach and bowel effects dominate across this class.

Cost, all-in

Brand prices depend on the drug and your coverage. Compounded prices depend on the drug and the program.

RouteWhat you payRead
Medicare GLP-1 Bridge: Foundayo, Wegovy or Zepbound KwikPen$50 copay, eligible enrolleesJuly 1, 2026 to Dec 31, 2027
Zepbound KwikPen, Lilly self-pay$299 to $449 a fill, with conditionsOct 15, 2026
Compounded tirzepatide, 33 programs$69 to $299 a month all-in; median $149Oct 15, 2026

Our price index covers tirzepatide. We do not quote Wegovy, Ozempic or compounded semaglutide prices here, because we have not read them under the same method. Lilly's self-pay savings end on December 31, 2026, and the $449 tier needs each refill within 45 days.

The current tirzepatide figures are in the price index. For coverage, see insurance and GLP-1s.

Who each option suits

These are situations, not recommendations. Which drug suits you is a decision for you and your clinician. Brand versus compounded comes after that.

  • You are on Medicare and have obesity without type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. The Bridge may give you Foundayo, Wegovy or the Zepbound KwikPen for $50. Check eligibility with CMS.
  • You are on Medicare and have one of those three conditions. You are not eligible for the Bridge, but your Part D plan might cover a GLP-1.
  • You want to avoid injections. Foundayo is the approved oral option in this list. Compounded oral GLP-1 products have no trial evidence behind them.
  • Your commercial plan covers a GLP-1. Check which one is on its formulary before you compare cash prices.
  • You pay cash. Compounded programs are usually cheaper. Check the pharmacy, the ingredient and the price at your maintenance dose.

What the evidence does not settle

  • Brand versus compounded results. No randomised trial has compared compounded semaglutide or compounded tirzepatide with the approved products.
  • Non-injected compounded forms. Whether compounded oral, sublingual or dissolving-tablet GLP-1s reach the bloodstream in useful amounts has not been shown.
  • Switching mid-course. Moving between brand and compounded, or between compounded products at different concentrations, has not been studied. The conversion depends on reading the concentration correctly.
  • Added ingredients. Benefits claimed for vitamins or amino acids added to compounded GLP-1s are untested.
  • The regulatory outcome. FDA's April 2026 proposal covers semaglutide, tirzepatide and liraglutide. Comments closed on July 30, 2026, and a Federal Register search on November 9, 2026 found no final decision.

Where it holds up

  • nothing verified yet

Where it does not

  • nothing verified yet

Questions readers actually ask

Which one is better?

Neither, in the abstract. The comparison table shows where each is stronger on a defined field; the right answer depends on your dose, your billing term and what your clinician advises.

Is one of these sponsoring this page?

No. No provider can buy a score, a placement or a review on this site.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Brand-Name vs Compounded GLP-1.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/compare/brand-vs-compounded-glp1/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4